- Company
- PalPal's sales are 5.1 billion won
- by Kim, Jin-Gu May 31, 2022 06:05am
- Hanmi Pharmaceutical is about to win the market for erectile dysfunction treatments. While "PalPal," the No. 1 item in the existing market, was leading, third-place Gugu chased second-place Chong Kun Dang's Cendom. According to IQVIA, a pharmaceutical market research institute, on the 28th, the domestic erectile dysfunction treatment marke
- Company
- Obesity treatment market expands 66% in 4 yrs
- by Chon, Seung-Hyun May 30, 2022 05:42am
- The obesity treatment market continues to grow with the launch of new products. The size of the new market has expanded by more than 60% over the past four years. According to IQVIA, a pharmaceutical research institute, on the 29th, the size of the obesity treatment market in the first quarter was 35.7 billion won, up 11.3% year-on-year. The
- Company
- Interleukin inhibitor market doubles in 2 years
- by May 30, 2022 05:41am
- Sales of interleukin inhibitors that are used to treat autoimmune diseases such as psoriasis have increased over twofold in 2 years. 1st generation drugs including Stelara, Cosentyx, Tremfya, and Skyrizi have all shown even growth. Market analysts have evaluated that the use of IL inhibitors has increased with the steady expansion of their indic
- Company
- Samjin recently filed a request against Janssen Korea
- by Kim, Jin-Gu May 30, 2022 05:41am
- Samjin has challenged Janssen's patent for the treatment of pulmonary arterial hypertension (Micronized Macitentan). In the past, generic companies have challenged Opsumit patents in all directions, but it has resulted in failure, drawing keen attention to the success of Samjin's challenge. According to the pharmaceutical industry on th
- Company
- The release of Singrix for NIP is expected
- by Moon, sung-ho May 30, 2022 05:41am
- Since the launch of the new government, the shingles vaccine market, called "a vaccine that is filial to parents," has been fluctuating. This is why global pharmaceutical companies are expected to release blockbuster vaccines in Korea in the second half of the year at a time when shingles are widely expected to be included in the NIP.
- Company
- Expanded indication for Jardiance
- by jung, sae-im May 29, 2022 05:15pm
- The SGLT-2 inhibitor Jardiance expanded the indication to HFpEF. Beringer Ingelheim Korea and Lilly Korea announced on the 26th that Jardiance has been approved by the MFDS to expand its indication as a treatment for chronic heart failure regardless of left ventricular contraction function (hereinafter referred to as heart rate). Jardiance wa
- Company
- Lorviqua, which is about to be reimbursed, has settled
- by Eo, Yun-Ho May 29, 2022 05:15pm
- The third-generation ALK inhibitor Lorviqua has settled in the Big Five Hospital. According to related industries, Lorviqua of Pfizer Korea passed the Drug Committee of Big 5 (DC), excluding Seoul St. Mary's Hospital such as Samsung Medical Center, Seoul National Cancer Center, and Chung-Ang University Hospital. As the adequacy of insuranc
- Company
- Janssen takes sole lead in the ₩50 billion PAH market
- by Kim, Jin-Gu May 27, 2022 05:56am
- Janssen Korea is solidifying its lead in the &8361;50 billion pulmonary arterial hypertension market in Korea. Whether the company will be able to maintain the share it has built up so far after terminating the co-promotion agreement with Handok remains a large variable. ◆The market for the rare disease pulmonary arterial hypertension
- Company
- Tremfya reimb. expanded to psoriatic arthritis
- by Eo, Yun-Ho May 27, 2022 05:56am
- The IL-23 inhibitor 'Tremfya’ is now applied insurance benefit in psoriatic arthritis. The Ministry of Health and Welfare issued a notice of amendment and extended the reimbursement standard of Tremfya as of the first of this month. With the amendment, Tremfya may now be reimbursed in patients with active or progressive psoriatic arth
- Company
- Soliris to Ultomiris...generation shift picks up speed
- by Kim, Jin-Gu May 26, 2022 05:56am
- The generation shift between Handok’s paroxysmal nocturnal hemoglobinuria treatments Soliris (eculizumab) and Ultomiris (ravulizumab) is gaining speed. With Ultomiris quickly replacing Soliris, Handok’s strategy of checking the release of Soliris’s biosimilars is also being considered a success. ◆Sales of Soliris drop 75%… replaced
